Anti-alpha Synuclein (phospho Y125) 抗体 (ab10789)

製品の概要

  • 製品名Anti-alpha Synuclein (phospho Y125) antibody
    alpha Synuclein 一次抗体 製品一覧
  • 製品の詳細
    Rabbit polyclonal to alpha Synuclein (phospho Y125)
  • アプリケーション適用あり: WB, ELISA, IHC-FoFr, ICC/IFmore details
  • 種交差性

    交差が予測される動物種: Mouse, Rat, Human
  • 免疫原

    Synthetic peptide conjugated to KLH derived from within residues 100 to the C-terminus of Human alpha Synuclein, phosphorylated at Y125.

    (Peptide available as ab17030.)

製品の特性

関連製品

アプリケーション

Our Abpromise guarantee covers the use of ab10789 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
WB Use at an assay dependent concentration. Detects a band of approximately 15 kDa (predicted molecular weight: 14 kDa).Can be blocked with Human alpha Synuclein (phospho Y125) peptide (ab17030).
ELISA Use at an assay dependent concentration.
IHC-FoFr 1/100.
ICC/IF Use at an assay dependent concentration. PubMed: 21114836

ターゲット情報

  • 機能May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation.
  • 組織特異性Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
  • 関連疾患Genetic alterations of SNCA resulting in aberrant polymerization into fibrils, are associated with several neurodegenerative diseases (synucleinopathies). SNCA fibrillar aggregates represent the major non A-beta component of Alzheimer disease amyloid plaque, and a major component of Lewy body inclusions. They are also found within Lewy body (LB)-like intraneuronal inclusions, glial inclusions and axonal spheroids in neurodegeneration with brain iron accumulation type 1.
    Parkinson disease 1
    Parkinson disease 4
    Dementia Lewy body
  • 配列類似性Belongs to the synuclein family.
  • ドメインThe 'non A-beta component of Alzheimer disease amyloid plaque' domain (NAC domain) is involved in fibrils formation. The middle hydrophobic region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
  • 翻訳後修飾Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress.
    Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers.
    Ubiquitinated. The predominant conjugate is the diubiquitinated form.
    Acetylation at Met-1 seems to be important for proper folding and native oligomeric structure.
  • 細胞内局在Cytoplasm, cytosol. Membrane. Nucleus. Cell junction, synapse. Secreted. Membrane-bound in dopaminergic neurons.
  • Information by UniProt
  • 参照データベース
  • 別名
    • Alpha synuclein antibody
    • Alpha-synuclein antibody
    • Alpha-synuclein, isoform NACP140 antibody
    • alphaSYN antibody
    • MGC105443 antibody
    • MGC110988 antibody
    • MGC127560 antibody
    • MGC64356 antibody
    • NACP antibody
    • Non A beta component of AD amyloid antibody
    • Non A4 component of amyloid antibody
    • Non A4 component of amyloid precursor antibody
    • Non-A beta component of AD amyloid antibody
    • Non-A-beta component of alzheimers disease amyloid , precursor of antibody
    • Non-A4 component of amyloid precursor antibody
    • Non-A4 component of amyloid, precursor of antibody
    • OTTHUMP00000218549 antibody
    • OTTHUMP00000218551 antibody
    • OTTHUMP00000218552 antibody
    • OTTHUMP00000218553 antibody
    • OTTHUMP00000218554 antibody
    • PARK 1 antibody
    • PARK 4 antibody
    • PARK1 antibody
    • PARK4 antibody
    • Parkinson disease (autosomal dominant, Lewy body) 4 antibody
    • Parkinson disease familial 1 antibody
    • PD 1 antibody
    • PD1 antibody
    • SNCA antibody
    • Snca synuclein, alpha (non A4 component of amyloid precursor) antibody
    • SYN antibody
    • Synuclein alpha antibody
    • Synuclein alpha 140 antibody
    • Synuclein, alpha (non A4 component of amyloid precursor) antibody
    • SYUA_HUMAN antibody
    see all

Anti-alpha Synuclein (phospho Y125) antibody 画像

  • All lanes : Anti-alpha Synuclein (phospho Y125) antibody (ab10789) at 1/1000 dilution

    Lane 1 : Negative control cells harboring empty vector
    Lane 2 : alpha synuclein expressed in Saccharomyces cerevisiae, strain BY4741 at 10 µg
    Lane 3 : A30P-synuclein expressed in Saccharomyces cerevisiae, strain BY4741 at 10 µg/ml

    Secondary
    HRP-conjugated goat anti-rabbit IgG polyclonal at 1/5000 dilution
    Developed using the ECL technique

    Performed under non-reducing conditions.

    Predicted band size : 14 kDa
    Observed band size : 15 kDa (why is the actual band size different from the predicted?)
    Additional bands at : 37 kDa (possible non-specific binding),55 kDa (possible non-specific binding).

    Exposure time : 3 minutes

    This image is courtesy of an Abreview submitted by Blagovesta Popova

    Proteins purified by Ni2+-NTA pull-down.

    See Abreview

  • ab10789 gave a positive result in ELISA against the immunising peptide (ab17030, blue line). It gave a negative result in ELISA against the non-modified equivalent peptide (ab17041, red line). This indicates that it is specific for the modified peptide. Not yet tested in other applications.
  • ab10789 gave a positive result in ELISA against the immunising peptide (ab17030, blue line). It gave a negative result in ELISA against the non-modified equivalent peptide (ab17041, red line). This indicates that it is specific for the modified peptide. Not yet tested in other applications.
  • IHC-FoFr image of ab10789 (1:100) staining on Rat brain sections. Images show staining of alpha synuclein (phospho Y125) in Hippocampus (Top Left), Hypothalamus (Top Centre) and Cortex (Top Right). Peptide pre-absorbtion was performed with the antibody to determine specificity to the modification on rat hippocampus sections. The antibody was incubated with No Peptide (Bottom Left), Unmodified peptide (Bottom Centre) and Modified Peptide (Bottom Right).

    See Abreview

Anti-alpha Synuclein (phospho Y125) antibody (ab10789) 使用論文

This product has been referenced in:
  • Kiely AP  et al. a-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol 125:753-69 (2013). ICC/IF ; Human . Read more (PubMed: 23404372) »
  • Schiess MC  et al. CSF from Parkinson disease patients differentially affects cultured microglia and astrocytes. BMC Neurosci 11:151 (2010). ICC/IF ; Human . Read more (PubMed: 21114836) »

See all 5 Publications for this product

Product Wall

Application Western blot
Loading amount 10 µg
Gel Running Conditions Non-reduced Denaturing (12,5 %)
Sample Saccharomyces cerevisiae Purified protein (Saccharomyces cerevisiae, strain BY4741)
Specification Saccharomyces cerevisiae, strain BY4741
Blocking step Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 20°C
Username

Dr. Blagovesta Popova

Verified customer

投稿 Mar 26 2014

Abcam has not validated the combination of species/application used in this Abreview.
Application Immunohistochemistry (PFA perfusion fixed frozen sections)
Sample Rat Tissue sections (Brain)
Specification Brain
Fixative Paraformaldehyde
Permeabilization No
Username

Dr. Sophie Pezet

Verified customer

投稿 Mar 20 2012

Application Immunohistochemistry (PFA perfusion fixed frozen sections)
Sample Rat Tissue sections (Brain)
Specification Brain
Username

Dr. Sophie Pezet

Verified customer

投稿 Nov 03 2011

Abcam has not validated the combination of species/application used in this Abreview.
Application Immunohistochemistry (Frozen sections)
Sample Human Tissue sections (Human brain (multiple system atrophy))
Specification Human brain (multiple system atrophy)
Fixative Acetone
Permeabilization No
Blocking step Milk as blocking agent for 30 minute(s) · Concentration: 20% · Temperature: 18°C
Username

Abcam user community

Verified customer

投稿 Aug 24 2011

Abcam has not validated the combination of species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (Human brain (Parkinson's disease and multiple sys)
Specification Human brain (Parkinson's disease and multiple sys
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citrate buffer
Permeabilization No
Blocking step Serum as blocking agent for 30 minute(s) · Concentration: 20% · Temperature: 18°C
Username

Abcam user community

Verified customer

投稿 Aug 24 2011

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"